



**21 June 2022**

**ASX ANNOUNCEMENT**

***ISSUE OF EMPLOYEE OPTIONS UNDER EMPLOYEE SHARE SCHEME***

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) (NSB or the Company) advises that, in accordance with the terms of the Company's Performance Rights Plan and Option (Plan), 1,000,000 unlisted options have been allocated to employees. The options have an exercise price of \$0.40 and will vest on achievement of various performance milestones.

The Company will release an Appendix 3G announcement in relation to this issue.

Additionally, 75,000 options previously issued under the plan have now lapsed and have therefore been cancelled by the Company.

This announcement is authorised for release by the NeuroScientific Biopharmaceuticals Limited Company Secretary.

Yours faithfully

A handwritten signature in black ink, appearing to read "Abby Macnish Niven".

Abby Macnish Niven  
Company Secretary

**END**

***Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals***

**Contacts**

Matthew Liddelow  
CEO and Managing Director  
[ml@neuroscientific.com](mailto:ml@neuroscientific.com)  
+61 8 6382 1805

Abby Macnish Niven  
CFO & Company Secretary  
[ir@neuroscientific.com](mailto:ir@neuroscientific.com)  
+61 8 6382 1805